While many believe at-home technologies such as remote patient monitoring or telehealth can decrease health care disparities, HD Nursing chairwoman and CEO Amy Hester told Medtech Insight that’s not always the case.
Hospital At Home: Great On Paper, Not In Practice
Former nurse advises device manufactures to take care during product development to close the health equity gap
To avoid a wider health equity gap for home-use devices, companies should make social determinants of health a key consideration in device development, former nurse Amy Hester says.
More from Diversity & Inclusion
• By
Chaos continues at the FDA’s device center as reinstated staffers begin daily commutes to comply with the administration’s return to office policy. Staffers can no longer publicly share their pronouns per Trump’s “Defending Women” executive order.
• By
10XBeta is helping to develop a modular mobile health care platform as part of a federal initiative to improve the quality of care in rural areas. Company CEO Marcel Botha told Medtech Insight that the product fits the company’s goals of bringing treatment to the people who need it most.
• By
Two US FDA device center websites have been restored under a restraining order. The pages now carry a disclaimer alleging they include "extremely inaccurate" content about gender; however, neither site includes any substantive discussion of trans issues.
• By
A six-year project aiming to establish a “less fragmented and more democratic” approach to clinical studies has commenced in the EU.
More from ESG
• By
A six-year project aiming to establish a “less fragmented and more democratic” approach to clinical studies has commenced in the EU.
• By
Several pages on the US FDA website related to diversity and inclusion are down, which aligns with Trump’s recent executive order on diversity, equity, and inclusion. However, the Department of Health says there's been a “short pause” in communications to allow the incoming team to get in place.
• By
While the US FDA will not require diversity action plans for clinical trials for a while, some companies are already sending them in, a new FDA report to Congress shows.